0001209191-20-060347.txt : 20201124
0001209191-20-060347.hdr.sgml : 20201124
20201124190044
ACCESSION NUMBER: 0001209191-20-060347
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201120
FILED AS OF DATE: 20201124
DATE AS OF CHANGE: 20201124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brewis Neil
CENTRAL INDEX KEY: 0001831247
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37718
FILM NUMBER: 201346198
MAIL ADDRESS:
STREET 1: C/O EDDEVA B920
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: F-star Therapeutics, Inc.
CENTRAL INDEX KEY: 0001566373
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 522386345
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 PARKWOOD DRIVE
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 44 1223 497400
MAIL ADDRESS:
STREET 1: 35 PARKWOOD DRIVE
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: Spring Bank Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20130108
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-20
0
0001566373
F-star Therapeutics, Inc.
FSTX
0001831247
Brewis Neil
C/O F-STAR THERAPEUTICS, INC.
EDDEVA B920, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE
X0
CB22 3AT
UNITED KINGDOM
0
1
0
0
Chief Scientific Officer
Common Stock
2020-11-20
4
A
0
19844
0.00
A
19844
D
Stock Option (right to buy)
0.08
2020-11-20
4
A
0
6307
0.00
A
2029-05-07
Common Stock
6307
6307
D
Stock Option (right to buy)
0.08
2020-11-20
4
A
0
70312
0.00
A
2030-07-01
Common Stock
70312
70312
D
Represents shares of common stock of F-star Therapeutics, Inc. (formerly Spring Bank Pharmaceuticals, Inc.) (the "Issuer") issued by the Issuer in the share exchange transaction that was completed on November 20, 2020 pursuant to the Share Exchange Agreement, dated as of July 29, 2020, by and among the issuer, F-star Therapeutics Limited ("F-star") and the holders of F-star shares, options, RSUs, and notes convertible into F-star shares.
The exercise price was originally in Pound Sterling and converted to U.S. Dollars using a conversion price of 0.844 according to Thomson Reuters.
This option was issued in replacement of an option to purchase shares of F-star Therapeutics Limited.
So long as Participant remains continuously a Service Provider 28% of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, May 7, 2019, and 2% of the total number of Shares under Award shall vest monthly thereafter
Twenty-five per cent (25%) of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of Shares under Award shall vest monthly thereafter, provided in each case that the Participant remains a Service Provider continuously from the Vesting Commencement Date to the relevant date.
/s/ Darlene Deptula-Hicks, Attorney-in-fact
2020-11-24